Oryzon.com Website Review

Epigenetics can be defined as the study of heritable changes in genome function that occur without a change in DNA sequence. Integrating epigenetic technology platforms results in the highest quality for our programs in drug development. Discovering and developing innovative personalized thera*eutics for patients with cancer or neurodegenerative disorders. ORYZON to present at the 2nd Neuroscience Innovation Forum in San Francisco ORYZON receives a new 1.14 M USD public grant to explore new indications for epigenetic inhibitors With an extensive patent portfolio, Oryzon Genomics is the biotechnology leader in Spain and the leading epigenetics company in Oryzon is the leader in the development of thera*eutics in the epigenetic target LSD1: Oryzon has a program in oncology, Iadademstat (ORY-1001), in Phase IIA in Leukemia and in small cell lung cancer (SCLC), another program in the field of neurodegenerative and neuroinflammatory diseases, Vafidemstat (ORY-2001), with three Phase IIA trials already started in multiple sclerosis, Alzheimer's disease and aggressiveness, and a third program, ORY-3001, currently finishing the preclinical regulatory phase, focused on the treatment of Oryzon also has other programs at early preclinical stage in other epigenetic thera*eutic targets. Oryzon is in permanent contact with the main pharmaceutical companies with the objective of establishing collaborative alliances based on its research and development programs. To that end, Oryzon also has an extensive network of contacts and collaboration agreements with public and private scientific reference institutions, either directly or under the framework of public grants at domestic as well as